Dr. Haim Danenberg Joins CBSET As Chief Scientific Adviser

LEXINGTON, Mass.--(BUSINESS WIRE)--CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, announced today that it has appointed Haim Danenberg, M.D., as chief scientific adviser, effective immediately.

Prof. Danenberg has served as Head of the Cardiovascular Research Center and Director of Interventional Cardiology at the Heart Institute of Hadassah Hebrew University Medical Center, Jerusalem. In addition, since 2004, he has served as a Visiting Scientist at the Harvard-MIT Center for Biomedical Engineering. Dr. Danenberg is on the editorial board of the Journal of Coronary Artery Disease and has co-authored nearly 100 manuscripts in peer-reviewed journals.

"We are honored to welcome Dr. Danenberg as chief scientific adviser," said Peter Markham, president, CEO and a co-founder of CBSET. "Dr. Danenberg has made major contributions to the development of percutaneous treatments in patients with acute coronary syndromes, and continues to be a leader in the evolution of transcatheter aortic valves. His depth of understanding of the incidence and clinical significance of post-procedural complications following deployment of structural heart devices will be a significant contribution to CBSETs leadership team adding further insight into the development of next-generation therapies. His professional focus and clinical expertise will advance CBSET's position in offering leading-edge services for these complex medical technologies."

"Prof. Danenberg's seminal contributions to basic science, applied biology and clinical medicine will strengthen CBSET's position as the preeminent international cardiovascular technology research institute," added Elazer Edelman, M.D., Ph.D., chairman and co-founder of CBSET; Director, Harvard-MIT Center for Biomedical Engineering; Professor of Medicine, Harvard Medical School and Brigham & Women's Hospital; and, Professor of Health Sciences and Technology, MIT.

To learn more about the services provided by CBSET, please contact: Dr. Erica Smith, Director, Business Development: +1-781-296-5319, [email protected]


CBSET — Concord Biomedical Sciences & Emerging Technologies — is the preclinical research leader in critically important therapeutic fields such as interventional cardiology, renal disease and dialysis, chronic drug-resistant hypertension, women's health, minimally invasive surgery, orthopedics, biological and synthetic tissue repair, drug delivery, bioresorbable devices, and combination medical device and drug-eluting products. The company was co-founded in 2006 by Peter Markham, Elazer Edelman, M.D., Ph.D., and Adam Groothuis, Ph.D. CBSET occupies a 35,000-square-foot, state-of-the-art facility near Boston that includes a vivarium, catheterization/imaging labs, surgical suites, dedicated labs for SEM, histopathology/pathology, and drug metabolism and pharmacokinetics. CBSET offers the latest equipment for fluoroscopy, echocardiography (TEE/TTE), electrophysiology, IVUS, optical coherence tomography (OCT), endoscopy/laparoscopy, surgical video recording, histology, microradiography, and SEM (Scanning Electron Microscopy). CBSET's professional staff of 55 FTEs includes Ph.D.s, D.V.M.s and recognized experts in device and drug safety, surgery, imaging, specialized histopathology and pathology, veterinary medicine, pharmacology, lead optimization, pharmacokinetics and drug metabolism, and regulatory consulting. These individuals provide the basis for successful scientific collaborations, rapid concept advancements, unparalleled consulting services, and expert dissemination of information and findings to regulatory and scientific bodies.